----
Current ValuationThe current P/E ratio is 137.51, above the reasonable range, cheaper than 1.53% of the time in the past 1 years, and the industry ranks 66/606, the industry Median -1.86.
137.51xP/E
$31.20Stock price
$0.23Earnings per share
137.51xP/E
Stock price$31.20Earnings per share$0.23
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -81.50x
- Typical range
- -1,098.16x–105.07x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03570105140
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BMRNUSBioMarin Pharma | 148.42x | 1.69% | $10.83B |
ARQTUSArcutis Biotherapeutics | 137.51x | 403.85% | $3.92B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
